CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large ...

RESULTS: Thirty-four patients (32%) were diagnosed with LMD based on CSF cytology, spinal MRI, or both. There were 21 discordant results. Nine patients (8.5%) with positive MRI had negative CSF ...

Target Selector™ platform shown to be potentially more sensitive than standard-of-care cytology in detecting mutations of brain metastases in cerebrospinal fluid SAN DIEGO, May 29, 2020 ...

Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference August 14, 2023 08:00 AM Eastern Daylight Time ...

“Current gold standard CSF cytology lacks the sensitivity needed to reliably diagnose LM in most clinical situations and lacks utility for disease monitoring,” said Marc H. Hedrick, M.D., Plus ...

Plus Therapeutics’ subsidiary, CNSide to launch CNSide cerebrospinal fluid assay platform in US: Houston Saturday, August 2, 2025, 14:00 Hrs [IST] Plus Therapeutics, Inc., a cli ...

Of 121 patients with cancer in whom cytology results were available, only 28 (23%) were detected by cytology, whereas Real-CSF correctly detected 69% of cancers in this group.

Leptomeningeal metastasis is difficult to diagnose and assess for treatment response using conventional methods such as cytology. In this study, 28 cerebrospinal fluid samples from 15 patients ...